Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pink Sheet Podcast: Roctavian CRL, COVID-19 Vaccine Adcomm Expertise, Pandemic Inspection Policies

Executive Summary

Pink Sheet reporters and editors discuss the surprise US complete response letter for a new gene therapy and the specialists who may be added to the FDA’s coronavirus vaccine advisory committee, and also look at facility inspections during the pandemic.

You may also be interested in...



Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.

Pink Sheet Podcast: Fall Vaccine Adcom, COVID-19 Vaccine Price Trend, Plasma DTC Ad Questions

Pink Sheet reporters and editors dig into the emerging coronavirus vaccine regulatory schedule, look at vaccine purchasing trends, and consider the curious case of a federal government billboard encouraging convalescent plasma donations.

Pink Sheet Podcast: Vaccine Makers On Capitol Hill, User Fee Renewal Negotiations Begin

Pink Sheet reporters and editors discuss the performance of the leaders of several coronavirus vaccine manufacturers during a recent congressional hearing and consider proposed changes to the generic and prescription drug user fee programs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel